Opella Reprices Term Loan B Facilities, Expects €12 Million Annual Savings
Opella announced on October 30, 2025, the successful repricing of its two Term Loan B facilities, totaling approximately €4.95 billion equivalent. The transaction is expected to generate annual interest savings of approximately €12 million.
PARIS – Opella announced on October 30, 2025, that it has successfully repriced its two 1st Lien Term Loan B facilities, representing approximately €4.95 billion equivalent. The repricing is expected to result in annual interest savings of approximately €12 million for the company.
The transaction involved adjustments to both the USD and EUR denominated tranches. The USD tranche was increased by $50 million to $3.8 billion and repriced with a 25-basis point reduction in margin. The EUR tranche was reduced by €43.5 million to €1.7065 billion, also benefiting from a 25-basis point margin reduction. Citi and BNP Paribas acted as global coordinators for the respective currency tranches.
According to Opella, the repricing is leverage neutral and does not involve any other material changes to the facilities' terms and conditions. The company stated that the transaction reflects strong investor demand and confidence in Opella’s credit profile.
Opella is a global self-care company operating in the Over-The-Counter (OTC) and Vitamins, Minerals & Supplements (VMS) markets. The company aims to empower consumers by simplifying self-care and is known for brands such as Allegra, Buscopan, and Doliprane.